2,529 Shares in Relx Plc $RELX Bought by AlphaCore Capital LLC

AlphaCore Capital LLC acquired a new stake in shares of Relx Plc (NYSE:RELX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,529 shares of the technology company’s stock, valued at approximately $137,000.

A number of other institutional investors have also added to or reduced their stakes in RELX. ABC Arbitrage SA boosted its position in shares of Relx by 188.9% during the 2nd quarter. ABC Arbitrage SA now owns 560,958 shares of the technology company’s stock valued at $30,482,000 after acquiring an additional 366,761 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Relx by 8.3% during the first quarter. Ameriprise Financial Inc. now owns 3,041,132 shares of the technology company’s stock valued at $154,129,000 after purchasing an additional 234,094 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Relx by 103.4% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 444,360 shares of the technology company’s stock valued at $22,400,000 after purchasing an additional 225,947 shares during the last quarter. Evelyn Partners Asset Management Ltd purchased a new position in Relx in the 2nd quarter worth approximately $11,649,000. Finally, Northern Trust Corp increased its holdings in shares of Relx by 9.2% in the 1st quarter. Northern Trust Corp now owns 2,394,097 shares of the technology company’s stock worth $120,686,000 after buying an additional 202,509 shares during the last quarter. 15.02% of the stock is currently owned by institutional investors.

Relx Price Performance

Shares of NYSE:RELX opened at $40.36 on Wednesday. The stock’s 50-day moving average price is $44.59 and its 200-day moving average price is $49.02. The company has a quick ratio of 0.42, a current ratio of 0.47 and a debt-to-equity ratio of 2.55. Relx Plc has a 12-month low of $39.31 and a 12-month high of $56.33.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating on shares of Relx in a report on Thursday, September 11th. Weiss Ratings lowered Relx from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, November 19th. Barclays reiterated an “overweight” rating on shares of Relx in a report on Tuesday, October 7th. Kepler Capital Markets raised Relx from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Finally, Wall Street Zen downgraded Relx from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.